HC Wainwright & Co. : Maintaining the Trevena (TRVN.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $9.00 to $5.00.
Trevena Analyst Ratings
HC Wainwright & Co. Maintains Buy on Trevena, Lowers Price Target to $5
Buy Rating Affirmed for Trevena Amid Strategic Focus on Promising Drug TRV045
Analysts Are Bullish on These Healthcare Stocks: Pliant Therapeutics (PLRX), Trevena (TRVN)
Trevena Analyst Ratings
HC Wainwright & Co. Maintains Buy on Trevena, Maintains $9 Price Target
Buy Rating Affirmed on Trevena as Focus Shifts to Promising Drug Candidate TRV045
Buy Rating Affirmed for Trevena Amid Strategic Focus on Promising TRV045 Development
Trevena Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Trevena, Maintains $9 Price Target
Analysts Offer Insights on Healthcare Companies: Trevena (TRVN), MoonLake Immunotherapeutics (MLTX) and Senseonics Holdings (SENS)
Analysts Offer Insights on Healthcare Companies: Trevena (TRVN) and Immunic (IMUX)
Analysts' Top Healthcare Picks: Ambrx Biopharma (AMAM), Trevena (TRVN)
JMP Securities Remains a Buy on Trevena (TRVN)
JMP Securities Remains a Buy on Trevena (TRVN)
Analysts Offer Insights on Healthcare Companies: Femasys (FEMY) and Trevena (TRVN)
JMP Securities Sticks to Their Buy Rating for Trevena (TRVN)
JMP Securities Keeps Their Buy Rating on Trevena (TRVN)
JMP Securities Reiterates Market Outperform on Trevena, Maintains $2 Price Target
No Data